West Pharmaceutical Services, Inc. (NYSE:WST) Q4 2022 Earnings Call Transcript

West Pharmaceutical Services, Inc. (NYSE:WST) Q4 2022 Earnings Call Transcript February 16, 2023

Operator: Good day, and thank you for standing by. Welcome to West Pharmaceutical Services Fourth Quarter 2022 Earnings Conference Call. . I would now like to hand the conference over to your speaker today, Quintin Lai, Vice President, Investor Relations. Please go ahead.

Quintin Lai: Thank you, Shannon. Good morning, and welcome to West’s Fourth Quarter and Full Year 2022 Conference Call. We issued our financial results this morning and the release has been posted in the Investors section on the company’s website located at westpharma.com. This morning, Eric Green and Bernard Birkett will review our financial results, provide an update on our business and present an update on our financial outlook for the full year 2023. There’s a slide presentation that accompanies today’s call, and a copy of that presentation is available on the Investors section of our website. On Slide 4 is our safe harbor statement. Statements made by management on this call and in the accompanying presentation contain forward-looking statements within the meaning of U.S. federal securities laws.

These statements are based on our beliefs and assumptions, current expectations, estimates and forecasts. The company’s future results are influenced by many factors beyond the control of the company. Actual results could differ materially from past results as well as those expressed or implied in any forward-looking statement made here. Please refer to today’s press release as well as any other disclosures made by the company regarding the risks to which it is subject, including our 10-K, 10-Q and 8-K reports. During today’s call, management will make reference to non-GAAP financial measures, including organic sales growth, adjusted operating profit, adjusted operating profit margin and adjusted diluted EPS. Reconciliations and limitations of the non-GAAP financial measures to the most comparable financial results prepared in conformity to GAAP are provided in this morning’s earnings release.

I’ll now turn the call over to our CEO, Eric Green.

Eric Green: Thank you, Quintin, and good morning, everyone. Thanks for joining us today. We will start on Slide 5. For over 100 years, the West name has come to mean so much to so many people. We have grown and expanded from manufacturing primary containment components to designing and manufacturing delivery systems. This remains the same today. As a global market leader who continues to define the evolution of our industry, our 10,000-plus team members are motivated by improving patient lives. The past few years have been a reminder that the world doesn’t stand still and the needs of the health care industry are evolving and growing in complexity with shifting treatment options from the hospital to home setting. We remain committed to the pursuit of scientific innovation and partnerships to address the changing needs of today and into the future.

Moving to Slide 6. Looking back at the year, I’m pleased to report that West delivered overall organic sales growth of approximately 8%. This growth was generated despite a rapidly shifting pandemic landscape. We started 2022 expecting COVID-19 volume growth, but instead decline in orders and demand from our customers actually resulted in a 15% decline in pandemic-related sales. Excluding COVID-19, we estimate that our base organic sales growth was low double digit, with mid-teens growth in proprietary products, and driving this base growth is demand for our high-value product offerings for both legacy as well as recently launched drugs, and we ended the year with a return to growth in Q4 in contract manufacturing. This performance is a result of the dedication and relentless focus of our team members across the globe.

We are connected by a strong responsibility and shared values that continue to help us succeed each day. I want to acknowledge these efforts and say thank you. Looking ahead, we remain well positioned with the right growth strategy around execute, innovate and grow. Our solid order book of committed orders reinforces the criticality of West’s components and devices to address our customers’ growing injectable drug demand, and we continue to deploy capital investments to support the increase in demand driven by the attractive end markets. Turning to Slide 7. In addition to our financial momentum, there were several other notable accomplishments in 2022. We shipped close to 47 billion components touching billions of patient lives. As scientific and technical leaders in the industry, our customers expect us to help solve their problems.

We continue to broaden insights with our expertise through our webinars, published articles and technical presentations. We partnered with Corning to build a next-generation leading elastomer-glass system. We launched Daikyo CZ 2.25 ml insert needle syringe to support the biologics market and secured 3 additional FDA-approved drugs using our SmartDose technology as we continue to bring additional value to our customers. Lastly, we donated $2.75 million, but more importantly, our team members continue to volunteer their time to help our local communities with the greatest needs. Our heartfelt thoughts are with all those impacted by the devastating earthquake in Turkey and Syria, where we have provided aid through UNICEF. Shifting to Slide 8.

We continue to factor environmental considerations into every aspect of our business. Over the past 5 years, we have made tremendous strides across the 6 priority areas and newly defined performance indicators. I’m pleased that we’re on target with 90% of our operational waste not being sent to landfills. Our pursuit of renewable energy alternatives has aided in a positive impact in the emission reduction. These efforts have been recognized with numerous ESG accolades in 2022. We look forward to sharing more detail in our corporate responsibility report to be published in the spring. Turning to Slide 9. We continue to address the growing market needs with today’s complex and sensitive molecules. At the recent Pharma Pack meeting, we introduced several new products for large volume delivery and complete vial containment solutions.

One available product is our West Ready Pack with Corning’s Valor ready-to-use vials. This will be the first of many products from our Corning partnership. The combination of these products eliminates the risk of delamination and reduces glass particulate in bulk filling lines. It is drug delivery innovations like this that ensures best-in-class performance with a value proposition to meet the increased regulatory expectations with a complete vial containment solution. Moving to Slide 10. We are introducing full year 2023 financial guidance. This guidance is based on demand trends as well as our current capacity levels. It’s also reinforced by our strong West and Daikyo participation rate in drug approvals, especially in biologics and biosimilars.

Photo by Amanda Jones on Unsplash

We expect full year overall organic sales growth of approximately 3% to 4%, which includes a $303 million year-over-year decline in pandemic-related sales. Excluding this impact, we expect mid-teens overall base organic sales growth with proprietary products growth in the high teens and high single-digit growth in contract manufacturing. 2023 will represent a transition year for our margin profile as we see a headwind from COVID-19 HVPs. That said, our expected margins for this year are significantly above pre-pandemic 2019 levels. This underscores the strength of our financial construct with annual margin expansion of 100 basis points or more per year. In 2019, we posted operating margin of 16.1%. In 2023, we expect operating margin of 23% to 24%, which would represent an increase of approximately 800 basis points over a 4-year period.

Also, today we announced that the Board of Directors has authorized a new share repurchase plan as our prior plan was completed last year. This program is authorized for up to $1 billion of share repurchase. We note that this new program does not have a specified end date. As comparison, in 2022, our 12-month program was completed at $203 million of buybacks. And in 2021, our 12-month program was completed at $137 million of buybacks. This new $1 billion program will provide for a continuation of our share count-neutral strategy, which is assumed in our 2023 full year financial guidance. We believe this program will also provide flexibility for incremental share repurchases depending on various factors such as economic and market conditions.

Turning to Slide 11. As you can see from our guidance, we seek continued base momentum in 2023, and we’re planning for a further additional growth as our customers are preparing for expanded success of their current biologics portfolio and drug launches. As such, we continue to drive forward to complete the installation of our capital expansion plans for additional HVP capacity. The picture shows the progression of our ongoing efforts. On my recent visit to Kinston, it was impressive to see the additional space added to accommodate the installation of new manufacturing equipment to address the growth of HVPs and plungers. Together with other site expansions, this will support future demand across our global manufacturing network. Now I’d like to turn the call over to Bernard.

Bernard Birkett: Thank you, Eric, and good morning. We will first look at Q4 2022 revenues and profits, where we saw low single-digit organic sales growth and a decline in operating profit and diluted EPS. I will take you through the drivers impacting sales and margin in the quarter as well as some balance sheet takeaways. And finally, we will review our 2023 guidance. First off, Q4. Our financial results are summarized on Slide 12 and the reconciliation of non-U.S. GAAP measures are described in Slides 20 to 23. We recorded net sales of $708.7 million in the quarter, representing organic sales growth of 2.6%. COVID-related net revenues are estimated to have been approximately $55 million in the quarter, an approximate $69 million reduction compared to the prior year.

These net revenues include our assessment of components associated with vaccines, treatment and diagnosis of COVID-19 patients, offset by lower sales to customers affected by lower volumes due to the pandemic. Looking at Slide 13. Proprietary Products sales grew organically by 1.8% in the quarter. High-value products, which made up approximately 72% of Proprietary Product sales in the quarter were flat compared to the prior year due to the reduction in COVID-related net revenues. Looking at the performance of the market units, the generics market unit delivered double-digit growth led by ambition components and admin systems, while the pharma market unit experienced high single-digit growth led by NovaPure and Westar components. And the biologics market unit saw a mid-single-digit decline due to a reduction in sales related to COVID-19 vaccine.

Our Contract Manufacturing segment experienced net sales growth of 7% in the fourth quarter, primarily driven by sales of health care-related medical devices. Our adjusted operating profit margin of 22.4% was a 350 basis point decrease from the same period last year. Finally, adjusted diluted EPS declined 13.2% for Q4. Excluding stock-based compensation tax benefit of $0.06 in Q4, EPS declined by approximately 13.6%. Now let’s review the drivers in both our revenue and profit performance. On Slide 14, we show the contributions to sales growth in the quarter. Sales price increases contributed $28.1 million or 3.8 percentage points of growth. Offsetting price was a foreign currency headwind of approximately $41.3 million and a negative mix impact of $8.9 million, primarily due to a reduction in COVID-19-related net demand.

Looking at margin performance, Slide 15 shows our consolidated gross profit margin of 37% for Q4 2022, down from 41.1% in Q4 2021. Proprietary Products fourth quarter gross profit margin of 41.6% was 470 basis points lower than the margin achieved in the fourth quarter of 2021. The key drivers for the decline in Proprietary Products gross profit margin were unfavorable mix from a reduction in sales related to COVID-19 vaccine and continued inflationary pressures on our plant costs, including raw materials, labor and overheads. The headwinds were partially offset by sales price increases. Contract Manufacturing fourth quarter gross profit margin of 15.4% was 110 basis points below the margin achieved in the fourth quarter of 2021. The decrease in margin is largely attributed to mix of products sold.

Now let’s look at our balance sheet and review how we’ve done in terms of generating more cash. On Slide 16, we have listed some key cash flow metrics. Operating cash flow was $724 million for the year, an increase of $140 million compared to the same period last year, a 24% increase. Operating cash flow in the period benefited from our working capital improvement. In 2022, we spent over $284 million on capital expenditures, a 12% increase over 2021. We continue to leverage our CapEx to increase our high-value product manufacturing capacity within our existing facilities in the U.S., Germany, Ireland and Singapore. Working capital of approximately $1.4 billion increased by $252.6 million from 2021, primarily due to higher accounts receivable from our increased sales, higher inventory levels and an increase in our cash position.

Our cash balance at December 31 of $894.3 million was $131.7 million higher than our December 2021 balance. The increase in cash is primarily due to our operating results in the period, offset by our share repurchase program and higher CapEx. Turning to guidance. Slide 10 provides a high-level summary. Full year 2023 net sales guidance will be in a range of $2.935 billion and $2.96 billion. There is an estimated headwind of $30 million based on current foreign exchange rates. We expect organic sales growth to be approximately 3% to 4%. We expect our full year 2023 adjusted diluted EPS guidance to be in a range of $7.25 to $7.40. Also, our CapEx guidance is $350 million for the year. There are some key elements I want to bring your attention to as you review our guidance.

Estimated FX headwind on EPS has an impact of approximately $0.11 based on current foreign currency exchange rates. We expect full year COVID-19 related net sales to be approximately $85 million compared to $388 million in 2022. And our guidance excludes future tax benefits from stock-based compensation. I’d now like to turn the call back over to Eric.

Eric Green: Great. Thank you, Bernard. To summarize on Slide 17, the solid financial performance shared today continues to reaffirm that our growth strategy is working. We have a durable base business proven by our market-led approach which is delivering unique value to our customers. Our global operations team is efficiently manufacturing and delivering products in this complex environment with a focus on service and quality. And we’re continuing to progress capital spending across our operations to meet current and anticipated future growth. We realize that our products in pursuit of scientific innovations are critical to health care across the globe which is why we’re so committed to support patient health today and well into the future. Shannon, we’re ready to take questions. Thank you.

See also 12 Countries that Export the Most Textiles and 12 Countries that Export the Most Tea.

Q&A Session

Operator: . Our first question comes from the line of Larry Solow with CJS Securities.

Lawrence Solow: Congrats on a good quarter, better than obviously we expected. Eric, maybe could you just discuss sort of the long-range outlook. HVP, I know you mentioned 72% of volume in the — revenue in the quarter. But could you speak to it more on a volume basis and particularly some of the faster growing and higher margin, NovaPure and as you kind of send up the HVP curve, if you will, I mean, the opportunities over the next several years?

Eric Green: Yes. Thanks, Larry. No, you’re right. So if you think about HVP right now, the amount of units produced from our manufacturing sites is roughly around 23% of the total volume. But as you rightly pointed out, it was about 72% of our sales in the last quarter. And the higher growth part of that high-value product spectrum of the portfolio is coming from our FluroTec all the way up to NovaPure. So NovaPure is becoming more meaningful. Obviously, it was a major element of the COVID-19 response. But with the number of biologic launches, the NovaPure is becoming a very attractive solution for our customers. So I would say it’s early. The investments that we’re making, particularly in our HVP plants of Kinston, Jersey Shore are around NovaPure plungers and other types of plungers to address future launches. So that’s where the growth is really out portion is coming from the higher end of HVP as we speak.

Lawrence Solow: Okay. And how about just — yes, go ahead, I’m sorry.

Bernard Birkett: If you look at the CapEx guidance as well that approximately 70% of that CapEx number is really to support growth initiatives and productivity improvements. And much of that is around high-value products. So that ties in with the outlook that we would see for the next number of years putting that capacity in place.

Lawrence Solow: And what about just generally in the industry, I know the trends have been biologics are obviously growing faster than overall drugs. Has that trend like accelerated over the last few years? Or what’s the outlook there on a general macro level?

Eric Green: Yes. We believe the biologics and biosimilar space is going to be the fastest-growing area for new drug launches. If you think about the last year, though, however, it was interesting to see the number of ANDAs and also small molecules approved into the market. And fortunately, we have a strong position in those areas also. But I think if you kind of fast forward, you’ll still see biologics and biosimilars be the fastest growth area in our space.

Lawrence Solow: Got it. And then just lastly, can you just give us sort of a — just a brief update on the call, not sure if you had talked a little bit about Corning at all, but just sort of where we stand there? I know I think last year, you had even called out how much you’re spending on R&D. I’m sure it’s a pretty incremental piece this year as well. But I don’t know what you could speak to on the R&D side and the cost, but maybe just sort of where we stand qualitatively, the revenue outlook and how big this could be over the next few years?

Eric Green: Yes, Larry, it’s a really strong partnership, and we’re really pleased that earlier this month, we were able to announce our first product launch of combining our West NovaPure stopper in Corning’s Valor vials, which — what we label as our Ready Pack solution. And just to remind everyone that this is kind of a seeder or a seed program that we use in the development of new molecules. So this has been very successful for us in the past. We’re leveraging this channel to introduce this combination going forward. It’s a great testament of the focus between the 2 firms on really bringing the product together as a complete solution. And so while this is early, we saw more work to do. We have a number of launches that we have scheduled, whether it’s in 2023, 2024.

Ultimately, where we want to get to is a complete solution with the 1 drug master vial. So it’s a complete fully characterized system. And so that we’ll continue required investments. And so if you look at our R&D spend in 2023, it will be slightly up, and a good portion of that incremental piece will be around the West-Corning partnership.

Operator: . Our next question comes from Matt Larew with William Blair.

Matthew Larew: I just wanted to ask just you referenced sort of the committed order book. And I’m curious maybe if you compare the composition of that order book today versus pre-COVID, obviously, on the non-COVID part? Maybe just in terms of what NovaPure and FluroTec demand look like? I guess the question is, out of the potential FluroTec customers who you start engaging with, what does the conversion look like — excuse me, on the NovaPure side, what does the conversion look like, in terms of folks who ultimately end up choosing to go with NovaPure perhaps versus a few years ago?

Eric Green: Yes. Thank you for the question. So when I look at the order book versus pre-pandemic and then strip out the COVID piece, overall, it’s a net increase where we were at that point in time. When you look at the composite of the growth of that order book, it is really driven by our high-value products, and particularly the higher end HVPs, we’re seeing a healthy growth in plungers, not just in the NovaPure sector, but in the other categories of HVP. But — so from an order — committed order book perspective, that’s the kind of the characteristics we’re seeing right now. In regards to the adoption rate, it’s actually quite high. So our participation rate, particularly in the biologics and biosimilars is very, very strong.

And what we are doing is we’re seeding with the NovaPure portfolio. And once that is locked in, in the development phase as they go through into commercialization, that’s the end result. Better outcomes for our customers, obviously, better compatibility with the drug molecule. So we’re very excited to see the continuation of that adoption of NovaPure and that’s hence the reason why we’re putting these investments in place, and we’re seeing more of a transition from vials to prefilled syringes which will require our plungers. So that’s where we are, but it’s a very, very healthy growth profile of the higher end of HVPs.

Matthew Larew: And then just maybe a cleanup one on the equipment issues you referenced on the third quarter call. How does that end up impacting fourth quarter results relative to expectations of where do things stand now halfway into the first quarter of ’23?

Eric Green: Yes. So those issues are resolved. The team did a really great job to resolve the issues and get our manufacturing facilities back up online. Fully validated, characterized and be able to support commercial production. That was done in, I’d say, mid part of Q4, a little bit later in that part of the quarter. So we’re full out right now in Q1. And I’m excited that we have that at this point to allow us to get some of the backlog caught up in the early parts of this year.

Operator: Our next question comes from the line of Jacob Johnson with Stephens.

Jacob Johnson: Congrats on a nice quarter. Maybe kind of following up on that last question. Just Bernard, as we think about how the year plays out, anything you’d highlight in terms of seasonality or kind of margin progression, revenue progression throughout the year? And maybe along those same lines, can you just remind us when you have the toughest comps from COVID that you’ll be lapping from 2022?

Bernard Birkett: Yes. So I think from a cadence perspective, going back to what we would have seen kind of pre-COVID where first quarter is usually a little bit lighter, picks up a bit in the second quarter and then levels out in Q3 and Q4. And from a comp perspective, I think a lot of the COVID revenues we would have had would have been in the first half of 2022. So that’s where, I won’t say challenges, but that’s where the biggest comps are going to be from that perspective, and then some in Q3 and then obviously lighter in Q4.

Jacob Johnson: Got it. And then on contract manufacturing, nice to see a return to growth there, uptick in revenue in the quarter. I think gross margin was down sequentially. Can you just hit on what drove both? And maybe related, you’re pointing to, I think, pretty robust growth in 2023. Were there some investments you’re making for this year and kind of again along the same lines, what’s driving the growth in that business in 2023?

Bernard Birkett: Yes. I think as you’ll remember, when we were talking through 2022, a lot of the challenges we face within contract manufacturing is really around 1, 2 — 1 customer mainly and a shift in their business. And so as that kind of have tailed off towards the back end of the year, it allows us to be able to return to growth. And then we actually saw demand increase from our existing customer base probably a little bit ahead of where we would have anticipated going into the fourth quarter. So that was again positive to see. And what we would expect as we move into 2023 that we will be seeing mid-single-digit growth for our contract manufacturing on our existing business and then layering in new business at the same time. So we continue to make some investments in that area.

Operator: Our next question comes from the line of Paul Knight with KeyBanc.

Paul Knight: The question is, I touched on it, I guess, is COVID probably starts flow then they manufacture more product Q2, Q3, right? And then less in Q4. That’s the question one. And then the other would be regarding this prefilled syringe market is that really what you’re seeing as biggest opportunity right now?

Eric Green: Yes. Paul, that’s a good question. So the first part is that when we think about the COVID, it’s — we’re looking about right now, approximately $85 million for 2023 is relatively kind of evenly spread. We can’t get any more granular than that at this point. But as you know, we were much higher than that last year. So we do have the capabilities to manufacture accordingly. In regards to the prefilled syringe, when you think about our investments, particularly in the last couple of years and working with some of the launches in anticipation around plungers, which obviously supports the prefilled syringe space is actually — we’re anticipating higher growth in that area. And that is — equipment is coming online as we speak.

I mentioned a little bit in my prepared remarks about Kinston, a lot of the additional equipment in there is really geared around plungers. And so I’m excited to build support that part of the market as we see the prefilled syringe market continue to expand with high growth. So we’re going to play in that, and we’re prepared for it, and that’s where investments are really focused on today.

Operator: Our next question comes from the line of Derik De Bruin, Bank of America.

Derik De Bruin: So can you talk a little bit about sort of like pricing? You got about 4% in 4Q. How should we think about that in ’23? Are you — I know you were debating taking some higher pricing. You’re looking at your pricing dynamics as things are going forward. And I guess, have you done that? And are you — have you seen any pushback from your customers?

Eric Green: Yes. Thanks for the question. So you’re right. We have implemented in the fourth quarter of 2022, obviously, discussions with our customers about the 2023 calendar year. Our net price increase will go up in 2023, and that is obviously for all the right reasons, particularly with some of the inflationary challenges and so forth that I think all industries are being faced with. So I think the team responded appropriately. I believe we took a very — very well-balanced approach. We do have certain customers on contracts, so we did have some limitations. However, overall, with the new pricing team and strategy we put in place a couple of years ago, we’re starting to see that pay off. So that will be rolling out as we speak and already this quarter and will be rolling throughout 2023. But Bernard, do you want to provide more color on that?

Bernard Birkett: Yes. So our — I think in the fourth quarter, we said we did about 3.8% of pricing. We’re targeting 5% to 6% on price as we move through 2023. So it is a bit of a step up. And part of that is to take into account the inflationary cost pressures that we’re also seeing. But as Eric said, you can see the trajectory and our price increases over the last number of years and how we’re approaching that. That’s also been on the increase.

Derik De Bruin: Great. Just a little bit of an accounting question. What was the tailwind from stock-based comp in ’22? And your initial tax rates are never what you end up being with for the full year. So is it comparable to think — is it reasonable to think you get a comparable benefit in ’23?

Bernard Birkett: We guide without it because it’s very hard for us to estimate it. If you look at — last year, it was about $0.22, I believe. So it’s — we guide without it for a reason because it is so hard for us to predict that’s kind of outside of our control.

Derik De Bruin: Got it. And if I can squeeze one more in, if you don’t mind. How should we think about the economics on the prefilled syringes? I mean, obviously, there’s a lot of new drugs coming out for metabolic disease, for obesity. And how should we think about your potential profitability or the revenues associated with one of those units? And just give us some way to sort of like ballpark what your — I mean what your revenue contribution could be on something like that?

Eric Green: Yes. So if you think about the prefilled syringe area and the plungers, we are — it depends on if it’s NovaPure, it’s pretty comparable to — we talk about the $0.88 to over $1 a unit. But if it’s not the NovaPure, other types of HVPs you have a very large range between, let’s call it, $0.40 per unit. So you can see the range that we’re operating in. From a margin perspective, again, if it is HVP that could range anywhere between 55% to 80%. So I’m giving you a very broad range because not all molecules have the same requirements. But what’s good around our investment thesis in our facilities, particularly on plungers is that the equipment and the processes are somewhat fungible. So we can leverage the existing assets we’re putting into the current drug launches, but also the anticipated areas of potential growth. So we’re positioned well.

Operator: Our next question comes from the line of John Sourbeer with UBS.

John Sourbeer: I guess maybe digging in a little bit more on the new capacity coming online in the CapEx. Any color just on pacing there for the year? And then just a follow-up on the equipment and the delays in 3Q. I think that was around the $30 million a month headwind. Can we assume now that this is up, that’s contributing around $30 million a month as well?

Bernard Birkett: Yes. The impact in Q3 was about $30 million. And that may vary depending on volume mix as we go through each quarter. So it’s hard to say, it’s $30 million each quarter. It would be difficult to commit to that at this point. But in saying that all of those problems that we had in Q3 have been resolved, as Eric kind of talked about earlier, and much of that happened as we progressed through Q4. And on the pacing of layering in new CapEx, that will happen as we move through 2023. So it’s not all at once. We’ll see some of it as we get into the back end of the second quarter particularly in Kinston, where we are getting new parts of our facility up and running with the equipment that we’ve installed there. And then as we progress through the year, there will be equipment layered in in the other HVP sites.

John Sourbeer: Got it. I appreciate it. And then I guess just maybe on COVID, it looks like you lowered the guidance there slightly. I guess just any thoughts on just where endemic levels go from here? How much more further drop do you think that you see coming down from COVID beyond 2023?

Bernard Birkett: It’s hard to estimate that. Like we’ve tried to — well, we’ve given our best estimate based on the information that we have today. If we thought it was going to drop any further, and we would have included that in the guidance. But based on what we see today, that’s where we think it’s going to play out.

Operator: Our next question comes from the line of David Windley with Jefferies.

David Windley: I hope you can hear me. I wanted to — I’ve got a couple of follow-ups, but I wanted to start with just asking if you would level set where the market units are with kind of generics having a strong end of the year and biologics down, those are kind of opposite directions than is normal. What’s the kind of relative sizing of your 4 segments of the business so we have a base to work off of?

Bernard Birkett: Yes. So if you look at biologics as we go into 2023, the biggest drop — or the biggest impact of COVID revenues being reducing is within the biologics segment. So we do see a reduction there. But if you back that out, we’re actually seeing very strong double-digit growth within the biologics segment for our core business. And then as we progress through ’23 on generics, again, we would be looking to see high single-digit, early double-digit growth, pharma, high single digits and then contract manufacturing, as we said earlier, mid-single-digit growth.

David Windley: Okay. And Bernard, so to apply those, so is it like I think biologics was 40% to 45%. I’m just looking for should I think about with the kind of COVID correction that it’s closer to the 40%? I’m just looking for kind of the percentages to apply those growth percentages to.

Bernard Birkett: Yes. It’s — biologics was mid-40s. It’s going to come back a slight bit. So you’re probably 40% to 45%. And then — pharma and contract was about 17% or 18%.

David Windley: That’s fine. I can follow up offline. On the installation of the equipment and Eric, we talked about in Kinston, the washing equipment in that process, I guess I was under the impression that that was specifically NovaPure and maybe even more specifically NovaPure plunger equipment, but Bernard’s answered the last question that it kind of varies that that $30 million a month will vary based on volume and mix, maybe I misunderstood what — how fungible that equipment is across your product lines? So perhaps you could further elaborate on that, please?

Eric Green: Yes. No, absolutely. So specifically the equipment that we’ve discussed about Q3, that was ongoing operations, not specifically just NovaPure. So you have washers that wash — pharmaceutical washing capability that supports really the high-value product portfolio. The vision that you — the washing equipment that you were able to see that is for NovaPure. So some of the equipment is not fungible, but the core elements of the equipment is. But the growth that we’re having, based off of that equipment you looked at was really around the heavy part about the NovaPure. There’s some mix effect to it. And in the future investments we’re making that you saw in Kinston, that is — that’s, again, it’s a wide range of high-value products. FluroTec all the way up to NovaPure.

David Windley: Okay. So where I wanted to go with that, and I’ll make this my last one, is you’re losing the year-over-year COVID $300-ish million. Management has made the point that that has been very high gross margin, high incremental margin revenue. And so that creates, I think, contributes to this transition year on margin, Eric, that you mentioned in your prepared remarks, it seems like as you’ve put some of this equipment in place that was the hold up in 3Q, again, your last answer helps me to understand that better. But the revenue potential that that equipment unlocks is in the neighborhood of the revenue that you’re losing from COVID. I guess I now understand that maybe the margin on that revenue that’s coming in is perhaps not quite as rich as COVID, you could confirm that for me.

But just thinking about that and any other factors that we should be keeping in mind that influence that margin transition that are not as rich as the COVID revenue that is coming off?

Bernard Birkett: Yes. Dave, I’ll take that. And just going back to your last question on the split, just to clear that up. So the — as a percentage of proprietary sales, biologics is like mid-40s, generics, mid-20s and then pharma in a low 30% range, and that will get you to the split. With regard to your question on margin, it’s not as simple as one product coming out and another product going in. So we’re looking at it where there’s a mix impact, obviously, with the COVID revenues falling off and they have been higher-margin products. And we’ve also got the impact of inflation on our cost base. So you’ve got those 2 headwinds. And then as we alluded to, we talked about earlier is the increase in price that we’re seeing is above what we would normally see in our business.

So that helps offset some of this margin pressure. And then we have a very specific cost initiatives within our business, both from an operations manufacturing perspective and then on SG&A and R&D, really looking at cost control and cost management. That is delivering a number of efficiencies for us. So it helps us to overcome some of the margin challenges, but not all of them. And then that goes back to the point earlier, we’re not actually — margin is not stepping back to pre-COVID levels. We’re maintaining or holding on to a lot of the improvements that we made or the gains that we made.

Operator: Our next question comes from the line of Justin Bowers with Deutsche Bank.

Justin Bowers: Just piggybacking on Dave’s question. Can you help us understand and maybe it’s a range of sort of what the margin profile is on the C-19 business? And then with respect to the new capacity that’s coming online in 2023, can you help us understand how that phases in? Is it ratable? Or is it more second half loaded? Any color there would be helpful.

Bernard Birkett: So the margin on the COVID products would have been at the higher end of our margin range because a lot of that was NovaPure. So you could have been looking at range of 60% to 70% plus. And then on the CapEx piece on that being layered in, it’s — a lot of it has been layered in and commissioned as we speak. But to see the impact of it will be more so in the back half of the year when it’s fully operational and we’re able to put a lot of volume through.

Justin Bowers: Understood. And then just a quick one on China. Maybe a status update on the 2 plants over there? And any thoughts on how that impacts the progression of the year?

Eric Green: Yes. In China, the — our business impact for West overall is quite low. A lot of the activity that we’re manufacturing we do in China is for China. And so we have a really strong team there in our facility in Qingpu that continues to capture more share within the market. But our reliance on that — on our team there to export is very low. And again, overall value or revenues and profits to the corporation is very small. So that’s our impact in China. Our supply chain, if you think about procuring materials, is not heavily dependent on that part of the world. The team has done a really good job. Many of our products are co-located to our manufacturing sites. So that’s how we’ve set up our procurement and supply chain of raw materials.

Operator: I would now like to turn the conference back over to Quintin Lai for closing remarks.

Quintin Lai: Thanks, Shannon, and thank all of you for joining us on today’s conference call. An online archive of the broadcast will be available on our website at westpharma.com in the Investors section. Additionally, you may access a replay for 30 days following this presentation by using the dial-in numbers and conference ID provided at the end of today’s earnings release. That concludes this call. Have a nice day.

Operator: This concludes today’s conference call. Thank you for participating. You may now disconnect.